Biocon Ltd
NSE:BIOCON

Watchlist Manager
Biocon Ltd Logo
Biocon Ltd
NSE:BIOCON
Watchlist
Price: 329.55 INR -1.91% Market Closed
Market Cap: 394.7B INR
Have any thoughts about
Biocon Ltd?
Write Note

Biocon Ltd
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biocon Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Biocon Ltd
NSE:BIOCON
Total Current Assets
â‚ą151.8B
CAGR 3-Years
26%
CAGR 5-Years
27%
CAGR 10-Years
20%
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
Total Current Assets
â‚ą327.1m
CAGR 3-Years
-23%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Transgene Biotek Ltd
BSE:526139
Total Current Assets
â‚ą8.5B
CAGR 3-Years
998%
CAGR 5-Years
328%
CAGR 10-Years
N/A
Z
Zenotech Laboratories Ltd
BSE:532039
Total Current Assets
â‚ą304.5m
CAGR 3-Years
67%
CAGR 5-Years
4%
CAGR 10-Years
17%
Hester Biosciences Ltd
NSE:HESTERBIO
Total Current Assets
â‚ą2.2B
CAGR 3-Years
9%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Panacea Biotec Ltd
NSE:PANACEABIO
Total Current Assets
â‚ą5B
CAGR 3-Years
-6%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
No Stocks Found

Biocon Ltd
Glance View

Market Cap
395.7B INR
Industry
Biotechnology

In the bustling world of biotechnology, Biocon Ltd. stands as a beacon of innovation, rooted in its Indian origins yet extending its influence globally. Founded in 1978 by Kiran Mazumdar-Shaw, a visionary with a degree in fermentation science, Biocon began its journey as a maker of enzymes before transforming into a formidable force in biopharmaceuticals. This transformation was driven by the company's emphasis on research and development, leading to groundbreaking advancements in biosimilars, generics, and novel biotherapeutics. These products cater to critical areas such as oncology, diabetes, and autoimmune diseases. The company's success hinges on its ability to blend scientific rigor with entrepreneurial flair, enabling it to deliver high-quality, cost-effective solutions in a market traditionally dominated by Western giants. Biocon's revenue model is intricately woven from various strands of its expansive portfolio. A significant chunk emerges from its biologics division, where it manufactures biosimilars that serve as cost-friendly alternatives to expensive biologic drugs. Simultaneously, the company capitalizes on its expertise in small molecule APIs and branded formulations, which are integral to its generics business. Furthermore, collaborations and partnerships with global pharmaceutical companies amplify its reach, facilitating market access and regulatory navigation. Through these strategic undertakings, Biocon not only bolsters its financial performance but also reinforces its commitment to enhancing healthcare affordability and accessibility across the globe.

BIOCON Intrinsic Value
414.66 INR
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Biocon Ltd's Total Current Assets?
Total Current Assets
151.8B INR

Based on the financial report for Sep 30, 2024, Biocon Ltd's Total Current Assets amounts to 151.8B INR.

What is Biocon Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
20%

Over the last year, the Total Current Assets growth was 8%. The average annual Total Current Assets growth rates for Biocon Ltd have been 26% over the past three years , 27% over the past five years , and 20% over the past ten years .

Back to Top